Ian Frew

Current Position

Full Professor for Oncogenic Signaling (W3), BIOSS and Dept. Internal Medicine I

Academic Education

1994 - 1997

Bachelor of Science (Honours in Molecular Biology and Biochemistry), Australian National University, Canberra, AUS

Advanced Qualifications

1998 - 2003

PhD, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, AUS

Postgraduate Positions

2017 - present	Full Professor, Medical Center - University of Freiburg
2010 - 2016	Assistant Professorship of the Swiss National Science Foundation, CH
2010 - 2016	Assistant Professorship of the Zurich Center for Integrative Human Physiology, Institute of Physiology, University of Zurich, CH
2003 - 2009	Postdoctoral Research Fellow, Institute of Cell Biology, Swiss Federal Institute of Technology (ETH Zurich), Zurich, CH

Link to all publications of Ian Frew: PubMed

Publications on CRC 1453 funding

Mohl DA, Lagies S, Zodel K, Zumkeller M, Peighambari A, Ganner A, Plattner DA, Neumann-Haefelin E, Adlesic M, Frew IJ, Kammerer B. Integrated Metabolomic and Transcriptomic Analysis of Modified Nucleosides for Biomarker Discovery in Clear Cell Renal Cell Carcinoma. Cells (2023). Ganner A, Philipp A, Lagies S, Wingendorf L, Wang L, Pilz F, Welte T, …, Frew IJ, Walz G, Neumann-Haefelin E. SCD5 Regulation by VHL Affects Cell Proliferation and Lipid Homeostasis in ccRCC. Cells (2023). Seidel P, Rubarth A, Zodel K, Peighambari A, Neumann F, …, Adlesic M, …, Schell C, Börries M, …, Follo M, Albers J, Frew IJ. ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma. JCI Insight (2022). Bona A, Seifert M, Thünauer R, Zodel K, Frew IJ, Römer W, Walz G, Yakulov TA. MARVEL domain containing CMTM4 affects CXCR4 trafficking. Mol Biol Cell (2022). Dizin E, Olivier V, Roth I, Sassi A, Arnoux G, …, Wenger RH, Frew I, Feraille E. Activation of the Hypoxia-Inducible Factor Pathway Inhibits Epithelial Sodium Channel-Mediated Sodium Transport in Collecting Duct Principal Cells. JASN (2021). Hoefflin R, Harlander S, Abhari BA, Peighambari A, Adlesic M, …, Börries M, Köttgen A, Heikenwalder M, Frew IJ. Therapeutic Effects of Inhibition of Sphingosine-1-Phosphate Signaling in HIF-2α Inhibitor-Resistant Clear Cell Renal Cell Carcinoma. Cancers (2021). Ganner A, Gehrke C, Klein M, Thegtmeier L, Matulenski T, …, Walz G, Frew IJ, Neumann-Haefelin E. VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma. Sci Rep (2021).